Log in

KITOV PHARMA LT/S Stock Forecast, Price & News

+0.07 (+1.75 %)
(As of 09/28/2020 12:00 AM ET)
Today's Range
Now: $4.06
50-Day Range
MA: $5.92
52-Week Range
Now: $4.06
Volume311,600 shs
Average Volume1.44 million shs
Market Capitalization$63.84 million
P/E RatioN/A
Dividend YieldN/A
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KTOV



Sales & Book Value

Annual Sales$1 million
Book Value$5.56 per share



Market Cap$63.84 million
Next Earnings DateN/A
OptionableNot Optionable
+0.07 (+1.75 %)
(As of 09/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions

How has KITOV PHARMA LT/S's stock been impacted by COVID-19 (Coronavirus)?

KITOV PHARMA LT/S's stock was trading at $3.5510 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KTOV stock has increased by 14.3% and is now trading at $4.06.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of KITOV PHARMA LT/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KITOV PHARMA LT/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KITOV PHARMA LT/S

When did KITOV PHARMA LT/S's stock split? How did KITOV PHARMA LT/S's stock split work?

KITOV PHARMA LT/S shares reverse split on Saturday, August 22nd 2020. The 1-10 reverse split was announced on Friday, August 21st 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 21st 2020. An investor that had 100 shares of KITOV PHARMA LT/S stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for KTOV?

1 equities research analysts have issued 1 year target prices for KITOV PHARMA LT/S's shares. Their forecasts range from $30.00 to $30.00. On average, they expect KITOV PHARMA LT/S's share price to reach $30.00 in the next year. This suggests a possible upside of 638.9% from the stock's current price.
View analysts' price targets for KITOV PHARMA LT/S

Are investors shorting KITOV PHARMA LT/S?

KITOV PHARMA LT/S saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 402,000 shares, a decline of 37.5% from the August 31st total of 643,400 shares. Based on an average daily trading volume, of 17,660,000 shares, the days-to-cover ratio is presently 0.0 days.
View KITOV PHARMA LT/S's Short Interest

Who are some of KITOV PHARMA LT/S's key competitors?

What other stocks do shareholders of KITOV PHARMA LT/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KITOV PHARMA LT/S investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Onconova Therapeutics (ONTX), Southwestern Energy (SWN), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Vaxart (VXRT), Opko Health (OPK) and Ibio (IBIO).

Who are KITOV PHARMA LT/S's key executives?

KITOV PHARMA LT/S's management team includes the following people:
  • Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 67)
  • Mr. Isaac Israel, CEO & Director (Age 41)
  • Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 52)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 69)
  • Dr. Gil Ben-Menachem M.B.A., MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 52)


(KTOV) raised $13 million in an initial public offering (IPO) on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar served as the underwriters for the IPO.

What is KITOV PHARMA LT/S's stock symbol?

KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV."

Who are KITOV PHARMA LT/S's major shareholders?

KITOV PHARMA LT/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include UBS Group AG (0.18%), Two Sigma Securities LLC (1.61%), ETRADE Capital Management LLC (0.08%), Virtu Financial LLC (0.07%), First Republic Investment Management Inc. (0.03%) and StoneX Group Inc. (0.02%).

Which institutional investors are buying KITOV PHARMA LT/S stock?

KTOV stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Securities LLC, ETRADE Capital Management LLC, Virtu Financial LLC, First Republic Investment Management Inc., StoneX Group Inc., Bedel Financial Consulting Inc., and Raymond James Financial Services Advisors Inc..

How do I buy shares of KITOV PHARMA LT/S?

Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KITOV PHARMA LT/S's stock price today?

One share of KTOV stock can currently be purchased for approximately $4.06.

How big of a company is KITOV PHARMA LT/S?

KITOV PHARMA LT/S has a market capitalization of $63.84 million and generates $1 million in revenue each year. The company earns $-5,850,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis. KITOV PHARMA LT/S employs 10 workers across the globe.

What is KITOV PHARMA LT/S's official website?

The official website for KITOV PHARMA LT/S is www.kitovpharma.com.

How can I contact KITOV PHARMA LT/S?

KITOV PHARMA LT/S's mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company can be reached via phone at 972-3933-3121 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.